FDA Dubs Personalized Immunotherapy for Leukemia as “Breakthrough”

July 8, 2014 6:40 AM

15 0

After recording 89 percent of leukemia patients going into complete remission during initial trials, the U.S. Food and Drug Administration (FDA) put an experimental immunotherapy agent on the express train to market approval.

The CTL019, University of Pennsylvania's brain child, is personalized immunotherapy agent designated by US drug regulators as a "breakthrough therapy," meaning it will be reviewed faster and will get more attention from the FDA so it could be developed to be ready for the market.

Read more

To category page